Illumina (ILMN) Stock

Illumina, Inc. (NASDAQ:ILMN ) Wolfe Research 2024 Healthcare Conference Call November 20, 2024 9:20 AM ET Company Participants Ankur Dhingra - Chief Financial Officer Conference Call Participants Doug Schenkel - Wolfe Research Doug Schenkel All right. Good morning, everybody.

The latest solution to enable comprehensive genomic profiling of tumors will be presented at the  annual meeting of the Association of Molecular Pathology Customer-led research and presentations at the conference will deliver the latest evidence and education in tumor profiling SAN DIEGO , Nov. 19, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it will release TruSight™ Oncology 500 v2 (TSO 500 v2), a new version of its flagship cancer research assay to enable comprehensive genomic profiling (CGP). The assay is currently under development, with global release planned for mid-2025.

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Illumina is the leader in the undisputed Next Generation Sequencing market. Grail divestment is behind, enabling a margin expansion and fueling a more robust cash flow generation. The stock was down after hours, as much good news has been priced in the recent rally.

Illumina's third- quarter revenues from the consumables business show robust growth, offset by the declining instruments business.

Illumina (ILMN) came out with quarterly earnings of $1.14 per share, beating the Zacks Consensus Estimate of $0.87 per share. This compares to earnings of $0.33 per share a year ago.

Illumina (ILMN) is trading down guiding a 3% decline in revenue. George Tsilis believes the company is still notable despite the market's reaction.

Core Illumina revenue of $1.1 billion for Q3 2024, down 2% from Q3 2023 and on a constant currency basis Core Illumina GAAP operating margin of 68.6% and non-GAAP operating margin of 22.6% for Q3 2024 Core Illumina GAAP diluted EPS of $4.03 and non-GAAP diluted EPS of $1.14 for Q3 2024 Lowered fiscal year 2024 Core Illumina revenue guidance to decline ~3% from fiscal year 2023; expect Q4 2024 Core Illumina revenue of approximately $1.07 billion Raised fiscal year 2024 Core Illumina non-GAAP operating margin guidance to a range of 21% to 21.5% Raised fiscal year 2024 Core Illumina non-GAAP diluted EPS guidance to a range of $4.05 to $4.15 SAN DIEGO , Nov. 4, 2024 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company") today announced its financial results for the third quarter of fiscal year 2024. The financial results for YTD 2024 and Q3 2023 and YTD 2023 include the financial results for GRAIL which was spun off on June 24, 2024.

New, groundbreaking technology delivers Illumina's most comprehensive genome yet ; early results from Broad Clinical Labs demonstrate a highly simplified workflow , ultra-long phasing, high-resolution insights into complex genomic variation, and enhanced long-range information   Illumina and customers will also showcase new details on complete proteomics solution and latest data on Fluent single-cell technology SAN DIEGO , Oct. 31, 2024 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced that it will present updates on several key innovations in whole-genome sequencing, proteomics, and single-cell technology at the American Society of Human Genetics (ASHG) Annual Meeting next week in Denver. The latest details will be presented alongside new data from key opinion leaders in next-generation sequencing (NGS), illustrating the potential impact of Illumina's emerging innovations.